• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    10/14/21 8:58:32 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care
    Get the next $TLC alert in real time by email
    CB/A 1 d208712dcba.htm FORM CB/A Form CB/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form CB

     

     

    TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM

    (AMENDMENT NO. 8)

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to file this Form:

     

    Securities Act Rule 801 (Rights Offering)

       ☐  

    Securities Act Rule 802 (Exchange Offer)

       ☒  

    Exchange Act Rule 13e-4(h)(8) (Issuer Tender Offer)

       ☐  

    Exchange Act Rule 14d-1(c) (Third Party Tender Offer)

       ☐  

    Exchange Act Rule 14e-2(d) (Subject Company Response)

       ☐  

    Filed or submitted in paper if permitted by Regulation S-T Rule 101(b)(8)

       ☐  

    Note: Regulation S-T Rule 101(b)(8) only permits the filing or submission of a Form CB in paper by a party that is not subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act.

     

     

    森投資股份有限公司

    (Name of Subject Company)

     

     

    Woods Investment Co., Ltd.*

    (Translation of Subject Company’s Name into English (if applicable))

    Republic of China

    (Jurisdiction of Subject Company’s Incorporation or Organization)

    Woods Investment Co., Ltd.

    (Name of Person(s) Furnishing Form)

     

    *

    This report is filed by the Registrant as successor issuer to Taiwan Liposome Company, Ltd. in connection with a share swap transaction between the two companies. Under Rule 12g-3(a), series B-1 special shares of the Registrant are now deemed to be registered under Section 12(g) of the Exchange Act.

    (CUSIP Number of Class of Securities (if applicable))

    George Yeh

    Director

    Woods Investment Co., Ltd.

    2F, No. 3 Yuanqu Street

    Nangang District,

    Taipei City, Taiwan 11503

    Republic of China

    +886 2 2655 7377 (ext:101)

    (Name, Address (including zip code) and Telephone Number (including area code) of

    Person(s) Authorized to Receive Notices and Communications on Behalf of Subject Company)

    Not applicable.

    (Date Tender Offer/Rights Offering Commenced)

     

     

     


    PART I – INFORMATION SENT TO SECURITY HOLDERS

    Item 1. Home Jurisdiction Documents

    The following documents are attached as exhibits to this Form CB:

     

    Exhibit Number

     

    Exhibit Description

    1.1*   Taiwan Liposome Company, Ltd. (“TLC”, or the “Subject Company”) Notice of the First Extraordinary General Meeting of 2021 (the “EGM”) to consider, among others, the proposed privatization previously mentioned in the Form 6-K dated July 6, 2021 (the “Share Swap”). This document was posted on the TLC company website on August 4, 2021.
    1.2*   TLC Handbook for the First Extraordinary General Meeting of 2021 (the “EGM Handbook”) to consider, among others, the Share Swap. This document was posted on the TLC company website on August 4, 2021, and hard copies of this document were circulated to shareholders in Taiwan on August 5, 2021.
    1.3**   Cover note of the EGM Handbook (Exhibit 1.2) addressed to non-Taiwanese shareholders (not including ADS holders). This document was posted on the TLC company website together with the EGM Handbook on August 4, 2021, and hard copies of the combined document were circulated to shareholders outside Taiwan on August 5, 2021.
    1.4*   First Amendment to the Share Swap Agreement, dated August 4, 2021, included as a supplement to the EGM Handbook (Exhibit 1.2). This document was posted on the TLC company website on August 4, 2021 as a supplement to the EGM Handbook.
    1.5**   Revised EGM Handbook. This document was posted on the TLC company website on August 6, 2021.
    1.6**   Cover note of the Revised EGM Handbook (Exhibit 1.5) addressed to non-Taiwanese shareholders (not including ADS holders). This document was posted on the TLC company website together with the Revised EGM Handbook on August 6, 2021.
    1.7**   Cover note of the Revised EGM Handbook (Exhibit 1.5) addressed to ADS holders. This document was posted on the TLC company website together with the Revised Handbook on August 6, 2021, and an electronic copy of the combined document was furnished to the ADS depositary for bulk print on August 6, 2021 and circulated to ADS holders by mail on or around August 6 2021.
    1.8***   TLC Meeting Minutes for the First Extraordinary General Meeting of 2021. This document was posted on the TLC company website on August 26, 2021.
    1.9****   Handbook on Woods Special Shares (the “Woods Special Shares Handbook”) containing information on the terms of series B special shares issuable by Woods (the “Woods Special Shares”) in the Share Swap. This document was posted on the TLC company website on September 14, 2021.

     

    2


    1.10****

       Cover letter addressed to non-Taiwanese shareholders (not including ADS holders) describing procedures applicable to them in order to receive the Woods Special Shares. This document was posted on the TLC company website together with the Woods Special Shares Handbook on September 14, 2021, and an electronic copy of the combined document was distributed to the non-Taiwanese shareholders or through their custodians in the manner instructed by them on or around September 16, 2021.

    1.11****

       Cover letter addressed to ADS Holders describing procedures applicable to them in order to receive the Woods Special Shares. This document was posted on the TLC company website together with the Woods Special Shares Handbook on September 14, 2021, and an electronic copy of the combined document was furnished to the ADS depositary for bulk print on September 14, 2021 and circulated to ADS holders by mail on or around September 16, 2021.

    1.12

       Conversion Notice, which includes materials that holders of Woods special shares must return in order to convert their special shares into Woods common shares (the “Conversion Handbook”). This document was posted on TLC company website on October 14, 2021, and hard copies of this document were circulated to Taiwanese holders of Woods special shares on or around October 13, 2021.

    1.13

       Cover note of the Conversion Handbook (Exhibit 1.12) addressed to non-Taiwanese holders of Woods special shares. This document was posted on the TLC company website on October 14, 2021, and electronic copies of the combined document was circulated to Non-Taiwanese holders of Woods special shares on or around October 13, 2021.

     

    *

    Previously filed with the Securities and Exchange Commission as an exhibit to Form 6-K on August 4, 2021 and incorporated by reference in this Form CB.

    **

    Previously furnished to the Securities and Exchange Commission as an exhibit to Form CB/A on August 6, 2021.

    ***

    Previously filed with the Securities and Exchange Commission as an exhibit to Form 6-K on August 26, 2021 and incorporated by reference in this Form CB.

    ****

    Previously filed to the Securities and Exchange Commission as an exhibit to Form CB/A on September 15, 2021.

    Item 2. Informational Legends

    The required legend is prominently included in Exhibits 1.2, 1.3, 1.5, 1.6 and 1.7.

    PART II – INFORMATION NOT REQUIRED TO BE SENT TO SECURITY HOLDERS

     

    Exhibit Number

      

    Exhibit Description

    2.1*    Press release, dated July 5, 2021, entitled “TLC Announces Details of Stock Swap Transactions”.
    2.2*    Filings with the Taipei Exchange through the Taipei Exchange’s Market Observation Post System (“MOPS”), dated July 5, 2021, disclosing the minutes of the Q&A session in the press conference.
    2.3**    Filings with the Taipei Exchange through MOPS, dated July 6, 2021, confirming the venue of the rescheduled 2021 Annual General Meeting and the EGM.

     

    3


    2.4***

       Filing with the Taipei Exchange through MOPS, dated July 22, 2021, disclosing certain information about the Share Swap.

    2.5****

       Filing with the Taipei Exchange through MOPS, dated August 4, 2021, disclosing the amendment of Share Swap Agreement, with the full document uploaded on the MOPS website.

    2.6*****

       Q&A of Share Swap and the Restructuring as of August 4, 2021 (incorporated by reference in the Handbook (Exhibit 1.2) and the Revised EGM Handbook (Exhibit 1.5)). An electronic copy of this document was posted on the TLC company website on August 4, 2021.

    2.7*****

       Filing with the Taipei Exchange through MOPS, dated August 6, 2021, disclosing the amendment of the EGM Handbook (Exhibit 1.5), with the full document uploaded on the MOPS website.

    2.8******

       Filing with the Taipei Exchange through MOPS, dated August 23, 2021, disclosing certain information about the Share Swap.

    2.9*******

       Filing with the Taipei Exchange through MOPS, dated September 6, 2021, disclosing certain information about the Share Swap closing date.

    2.10********

       Press release, dated September 8, 2021, entitled “TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares”.

    2.11*********

       Filing with the Taipei Exchange through MOPS, dated October 8, 2021, disclosing certain information about TLC delisting from TPEx and the share swap deal close.

     

    *

    Previously filed with the Securities and Exchange Commission as an exhibit to Form 6-K on July 6, 2021 and incorporated by reference in this Form CB.

    **

    Previously filed with the Securities and Exchange Commission as an exhibit to Form 6-K on July 8, 2021 and incorporated by reference in this Form CB.

    ***

    Previously filed with the Securities and Exchange Commission as an exhibit to Form 6-K on July 22, 2021 and incorporated by reference in this Form CB.

    ****

    Previously filed with the Securities and Exchange Commission as an exhibit to Form 6-K on August 4, 2021 and incorporated by reference in this Form CB.

    *****

    Previously furnished to the Securities and Exchange Commission as an exhibit to Form CB/A on August 6, 2021.

    ******

    Previously furnished to the Securities and Exchange Commission as an exhibit to Form CB/A on August 24, 2021.

    *******

    Previously furnished to the Securities and Exchange Commission as an exhibit to Form CB/A on September 7, 2021.

    ********

    Previously filed with the Securities and Exchange Commission as an exhibit to Form 6-K on September 8, 2021 and incorporated by reference in this Form CB.

    *********

    Previously filed with the Securities and Exchange Commission as an exhibit to Form 6-K on October 8, 2021 and incorporated by reference in this Form CB.

    PART III – CONSENT TO SERVICE OF PROCESS

    A written irrevocable consent and power of attorney on Form F-X was filed by Taiwan Liposome Company, Ltd. with the Securities and Exchange Commission on August 5, 2021.

    A written irrevocable consent and power of attorney on Form F-X was filed by Woods Investment Co., Ltd. with the Securities and Exchange Commission on September 15, 2021.

     

    4


    SIGNATURES

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    WOODS INVESTMENT CO., LTD.
    /s/ George Yeh
    Name: George Yeh
    Title: Director

    Date: October 14, 2021

     

    5

    Get the next $TLC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLC

    DatePrice TargetRatingAnalyst
    7/13/2021$11.00 → $7.50Buy → Neutral
    H.C. Wainwright
    7/7/2021Buy → Hold
    Laidlaw
    More analyst ratings

    $TLC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Taiwan Liposome downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Taiwan Liposome from Buy to Neutral and set a new price target of $7.50 from $11.00 previously

    7/13/21 7:44:05 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    Taiwan Liposome downgraded by Laidlaw

    Laidlaw downgraded Taiwan Liposome from Buy to Hold

    7/7/21 7:42:46 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    $TLC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TLC Announces TLC599 Agreement with Endo

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreement with Endo International plc (NASDAQ:ENDP) for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain. Under the terms of the agreement, signed with Endo's subsidiary Endo Ventures Limited (EVL), TLC will primarily be responsible for the development of the product and EVL will primarily be responsible fo

    6/13/22 6:30:00 AM ET
    $ENDP
    $TLC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have been published in the peer-reviewed journal Arthritis Research & Therapy. TLC599 is a proprietary BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) intended for the treatment of osteoarthritis pain. The results demonstrated statistically significantly reduced pain scores and oral pain medication use for up to 6 months wit

    3/7/22 4:57:07 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares

    This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exemption from the registration requirements of the Securities Act provided by Rule 802 thereof. No public offering of such securities will be made in the United States. Such transaction has not been and

    9/8/21 4:40:55 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    $TLC
    SEC Filings

    View All

    SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    CB/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    10/14/21 8:58:32 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    CB/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    10/8/21 4:00:37 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Taiwan Liposome Company, Ltd.

    6-K - Taiwan Liposome Company, Ltd. (0001722890) (Filer)

    10/8/21 11:56:31 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    $TLC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    1/7/22 8:15:09 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    11/12/21 6:05:15 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    10/20/21 4:08:25 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care